Search
Menu
Home
HTB
2018
March
14
14 March 2018
Contents
Editorial
14 March 2018: vol 19 no 5 – CROI 2018 part 1
Conference reports
25th Conference on Retroviruses and Opportunistic Infections (CROI 2018)
Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques
No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification
Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment
Twice-daily dolutegravir is effective and tolerable with rifampicin
Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin
Efavirenz 400 mg can be given with anti-tuberculosis treatment
Bictegravir at CROI 2018: switching studies and drug resistance analyses
PrEP at CROI 2018 (part 1): Access in Australia and the US
PrEP at CROI 2018 (part 2): Animal studies for future drugs
BHIVA best of CROI feedback workshops
Antiretrovirals
FDA approves ibalizumab in the US to treat multidrug HIV resistance
PDFs
14 March 2018: vol 19 no 5
HTB RSS
Early access
Community response to decimated US funding for HIV vaccine research
6 June 2025
Gates Foundation commits to providing lenacapavir as PrEP next year
3 June 2025
All early access reports
Current issues
June 2025
May 2025
April 2025
Back issues
Special report
Latest news on the US crisis and its impact on global health
30 May 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate